Skip to Content

Dexrazoxane Injection

Last Updated: August 13, 2020
Status: Resolved

Products Affected - Description
    • Zinecard injection, Pfizer, 250 mg, vial, 1 count, NDC 00013-8717-62 - discontinued
    • Zinecard injection, Pfizer, 500 mg, vial, 1 count, NDC 00013-8727-89 - discontinued
Reason for the Shortage
    • Cumberland Pharmaceuticals relaunched Totect in late-July 2017.
    • Fosun Pharma has dexrazoxane available.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional has dexrazoxane available.
    • Pfizer discontinued Zinecard in June 2020.
Available Products
    • Totect kit, Cumberland Pharmaceuticals, 500 mg, vial, (only for extravasation injuries) 1 count, NDC 66220-0110-01
    • Dexrazoxane injection, Fosun Pharma, 500 mg, vial, 1 count, NDC 72266-0101-01
    • Dexrazoxane injection, Hikma, 250 mg, vial, 1 count, NDC 00143-9247-01
    • Dexrazoxane injection, Hikma, 500 mg, vial, 1 count, NDC 00143-9248-01
    • Dexrazoxane injection, Mylan Institutional, 250 mg, vial, 1 count, NDC 67457-0207-25
    • Dexrazoxane injection, Mylan Institutional, 500 mg, vial, 1 count, NDC 67457-0208-50

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated August 13, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 30, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.